Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ben A Bahr

Showing results (1-10 of 81) with videos related to

Pageof 9
Sort By:
Current Alzheimer Research|October 31, 2009
Lysosomal modulatory drugs for a broad strategy against protein accumulation disordersBen A Bahr
Rejuvenation Research|June 24, 2014
A single pathway targets several health challenges of the elderlyBen A Bahr
Journal of Neurochemistry|October 23, 2002
The neuropathogenic contributions of lysosomal dysfunctionBen A Bahr, Jennifer Bendiske
Journal of Neuropathology and Experimental Neurology|May 29, 2003
Lysosomal activation is a compensatory response against protein accumulation and associated synaptopathogenesis--an approach for slowing Alzheimer disease?Jennifer Bendiske, Ben A Bahr
Acta Neuropathologica|May 13, 2004
Biphasic NF-kappaB activation in the excitotoxic hippocampusEbru Caba, Ben A Bahr
Antioxidants & Redox Signaling|February 21, 2006
Oxidative stress and lysosomes: CNS-related consequences and implications for lysosomal enhancement strategies and induction of autophagyDavid Butler, Ben A Bahr
Journal of Neuroscience Research|September 8, 2004
Repeated contact with subtoxic soman leads to synaptic vulnerability in hippocampusSubramani Munirathinam, Ben A Bahr
Journal of Molecular Neuroscience : MN|January 22, 2008
Gephyrin alterations due to protein accumulation stress are reduced by the lysosomal modulator Z-Phe-Ala-diazomethylketoneSophia Ryzhikov, Ben A Bahr
Current Molecular Medicine|October 7, 2006
Cannabinoid drugs and enhancement of endocannabinoid responses: strategies for a wide array of disease statesDavid A Karanian, Ben A Bahr
European Journal of Pharmacology|April 19, 2008
Protein kinase C is a common component of CGRP receptor desensitization induced by distinct agonistsSokhom S Pin, Ben A Bahr
Pageof 9

Showing results (1-10 of 81) with videos related to

Sort By:
Pageof 9
Current Alzheimer Research|October 31, 2009
Lysosomal modulatory drugs for a broad strategy against protein accumulation disordersBen A Bahr
Rejuvenation Research|June 24, 2014
A single pathway targets several health challenges of the elderlyBen A Bahr
Journal of Neurochemistry|October 23, 2002
The neuropathogenic contributions of lysosomal dysfunctionBen A Bahr, Jennifer Bendiske
Journal of Neuropathology and Experimental Neurology|May 29, 2003
Lysosomal activation is a compensatory response against protein accumulation and associated synaptopathogenesis--an approach for slowing Alzheimer disease?Jennifer Bendiske, Ben A Bahr
Acta Neuropathologica|May 13, 2004
Biphasic NF-kappaB activation in the excitotoxic hippocampusEbru Caba, Ben A Bahr
Antioxidants & Redox Signaling|February 21, 2006
Oxidative stress and lysosomes: CNS-related consequences and implications for lysosomal enhancement strategies and induction of autophagyDavid Butler, Ben A Bahr
Journal of Neuroscience Research|September 8, 2004
Repeated contact with subtoxic soman leads to synaptic vulnerability in hippocampusSubramani Munirathinam, Ben A Bahr
Journal of Molecular Neuroscience : MN|January 22, 2008
Gephyrin alterations due to protein accumulation stress are reduced by the lysosomal modulator Z-Phe-Ala-diazomethylketoneSophia Ryzhikov, Ben A Bahr
Current Molecular Medicine|October 7, 2006
Cannabinoid drugs and enhancement of endocannabinoid responses: strategies for a wide array of disease statesDavid A Karanian, Ben A Bahr
European Journal of Pharmacology|April 19, 2008
Protein kinase C is a common component of CGRP receptor desensitization induced by distinct agonistsSokhom S Pin, Ben A Bahr
Pageof 9